In-silico epitope-based vaccine is the cornerstone of modern vaccine development and is illuminating by a growing number of experimental and computational methods. The reverse vaccinology approach uses computational screening of the whole proteome of a pathogen to identify the proteins with the attributes of potential vaccine targets. The selection of the right components [antigenic determinants, linkers, and intramolecular adjuvants] results in the development of a multi-epitope vaccine construct with maximum efficacy and minimum adverse effects. We provide insight into the recent advancement in epitope-based vaccines and the procedure to design the modern or next-generation vaccine. The synergy between the computational screening of vaccine candidates and experimental verification to assess the immunogenic potential improves decision-making and reduces the cost and time of the development of new therapeutics
No takes yet. Share an insight, caveat, or question.
Ahlawat et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: